NDLI: Biomarkers, metabonomics, and drug development: Can inborn errors of metabolism help in understanding drug toxicity?

Content Provider	Springer Nature Link
Author	Vangala, Subrahmanyam Tonelli, Alfred
Copyright Year	2007
Abstract	Application of “omics” technology during drug discovery and development is rapidly evolving. This review evaluates the current status and future role of “metabonomics” as a tool in the drug development process to reduce the safety-related attrition rates and bridge the gaps between preclinical and clinical, and clinical and market. Particularly, the review looks at the knowledge gap between the pharmaceutical industry and pediatric hospitals, where metabonomics has been successfully applied to screen and treat newborn babies with inborn errors of metabolism. An attempt has been made to relate the clinical pathology associated with inborn errors of metabolism with those of drug-induced pathology. It is proposed that extending the metabonomic biomarkers used in pediatric hospitals, as “advanced clinical chemistry” for preclinical and clinical drug development, is immediately warranted for better safety assessment of drug candidates. The latest advances in mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy should help replace the traditional approaches of laboratory clinical chemistry and move the safety evaluation of drug candidates into the new millennium.
Starting Page	E284
Ending Page	E297
File Format	PDF
ISSN	12341234
Journal	The AAPS Journal
Volume Number	9
Issue Number	3
e-ISSN	15507416
Language	English
Publisher	Springer-Verlag
Publisher Date	2007-01-01
Publisher Institution	American Association of Pharmaceutical Scientists
Publisher Place	New York
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Biomarkers clinical chemistry drug develoment inborn errors of metabolism metabonomics toxicity Pharmacology/Toxicology Biochemistry Biotechnology Pharmacy
Content Type	Text
Resource Type	Article

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Biomarkers, metabonomics, and drug development: Can inborn errors of metabolism help in understanding drug toxicity?

Metabonomics Techniques and Applications to Pharmaceutical Research & Development

Cytochrome P450s and other enzymes in drug metabolism and toxicity

Method Validation and Measurement of Biomarkers in Nonclinical and Clinical Samples in Drug Development: A Conference Report

The Evolving Role of Drug Metabolism in Drug Discovery and Development

Successes Achieved and Challenges Ahead in Translating Biomarkers into Clinical Applications

Clinical Trial Simulation in Drug Development

Strategic Biomarkers for Drug Development in Treating Rare Diseases and Diseases in Neonates and Infants

Development Considerations for Nanocrystal Drug Products

Biomarkers, metabonomics, and drug development: Can inborn errors of metabolism help in understanding drug toxicity?

Similar Documents

Biomarkers, metabonomics, and drug development: Can inborn errors of metabolism help in understanding drug toxicity?

Metabonomics Techniques and Applications to Pharmaceutical Research & Development

Cytochrome P450s and other enzymes in drug metabolism and toxicity

Method Validation and Measurement of Biomarkers in Nonclinical and Clinical Samples in Drug Development: A Conference Report

The Evolving Role of Drug Metabolism in Drug Discovery and Development

Successes Achieved and Challenges Ahead in Translating Biomarkers into Clinical Applications

Clinical Trial Simulation in Drug Development

Strategic Biomarkers for Drug Development in Treating Rare Diseases and Diseases in Neonates and Infants

Development Considerations for Nanocrystal Drug Products

Biomarkers, metabonomics, and drug development: Can inborn errors of metabolism help in understanding drug toxicity?